• Race affects overall relapse risk and response to rituximab in iTTP.

  • Black patients may require closer monitoring, earlier retreatment, and alternative immunosuppression after rituximab.

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. When all episodes of iTTP were included, Black race was associated with shorter RFS (hazard ratio [HR], 1.60; 95% CI, 1.16-2.21); the addition of rituximab to corticosteroids improved RFS in White (HR, 0.37; 95% CI, 0.18-0.73) but not Black patients (HR, 0.96; 95% CI, 0.71-1.31). In de novo iTTP, rituximab delayed relapse, but Black patients had shorter RFS than White patients, regardless of treatment. In relapsed iTTP, rituximab significantly improved RFS in White but not Black patients. Race affects overall relapse risk and response to rituximab in iTTP. Black patients may require closer monitoring, earlier retreatment, and alternative immunosuppression after rituximab treatment. How race, racism, and social determinants of health contribute to the disparity in relapse risk in iTTP deserves further study.

1.
Tsai
H-M
,
Lian
EC-Y
.
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
.
N Engl J Med.
1998
;
339
(
22
):
1585
-
1594
.
2.
Furlan
M
,
Robles
R
,
Galbusera
M
, et al
.
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
.
N Engl J Med.
1998
;
339
(
22
):
1578
-
1584
.
3.
Rock
GA
,
Shumak
KH
,
Buskard
NA
, et al;
Canadian Apheresis Study Group
.
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
.
N Engl J Med.
1991
;
325
(
6
):
393
-
397
.
4.
Scully
M
,
Cataland
SR
,
Peyvandi
F
, et al
.
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura.
N Engl J Med.
2019
;
380
(
4
):
335
-
346
. https://doi.org/10.1056/NEJMoa1806311
5.
Deford
CC
,
Reese
JA
,
Schwartz
LH
, et al
.
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura
.
Blood.
2013
;
122
(
12
):
2023
-
2029
, quiz 2142.
6.
Zheng
XL
,
Vesely
SK
,
Cataland
SR
, et al
.
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
.
J Thromb Haemost.
2020
;
18
(
10
):
2496
-
2502
.
7.
Scully
M
,
McDonald
V
,
Cavenagh
J
, et al
.
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
.
Blood.
2011
;
118
(
7
):
1746
-
1753
.
8.
Benhamou
Y
,
Paintaud
G
,
Azoulay
E
, et al;
French Reference Center for Thrombotic Microangiopathies
.
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: results of a phase II, multicenter noncomparative study
.
Am J Hematol.
2016
;
91
(
12
):
1246
-
1251
.
9.
Reese
JA
,
Muthurajah
DS
,
Kremer Hovinga
JA
,
Vesely
SK
,
Terrell
DR
,
George
JN
.
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features
.
Pediatr Blood Cancer.
2013
;
60
(
10
):
1676
-
1682
.
10.
Scully
M
,
Cataland
S
,
Coppo
P
, et al;
International Working Group for Thrombotic Thrombocytopenic Purpura
.
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
.
J Thromb Haemost.
2017
;
15
(
2
):
312
-
322
.
11.
Benhamou
Y
,
Assié
C
,
Boelle
P-Y
, et al;
Thrombotic Microangiopathies Reference Center
.
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
.
Haematologica.
2012
;
97
(
8
):
1181
-
1186
.
12.
Benhamou
Y
,
Boelle
P-Y
,
Baudin
B
, et al
.
Cardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center
.
J Thromb Haemost.
2015
;
13
(
2
):
293
-
302
.
13.
Colling
M
,
Sun
L
,
Upadhyay
V
, et al
.
Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura
.
Transfusion.
2020
;
60
(
4
):
841
-
846
.
14.
Prentice
RL
,
Williams
BJ
,
Peterson
AV
.
On the regression analysis of multivariate failure time data
.
Biometrika.
1981
;
68
(
2
):
373
-
379
.
15.
Sun
L
,
Mack
J
,
Li
A
, et al
.
Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura
.
Blood Adv.
2019
;
3
(
9
):
1512
-
1518
.
16.
Klein
JP
,
Logan
B
,
Harhoff
M
,
Andersen
PK
.
Analyzing survival curves at a fixed point in time
.
Stat Med.
2007
;
26
(
24
):
4505
-
4519
.
17.
Jestin
M
,
Benhamou
Y
,
Schelpe
A-S
, et al;
French Thrombotic Microangiopathies Reference Center
.
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
.
Blood.
2018
;
132
(
20
):
2143
-
2153
.
18.
Rizopoulos
D
.
D: an R package for the joint modelling of longitudinal and time-to-event data
.
J Stat Softw.
2010
;
35
(
9
):
1
-
33
.
19.
Froissart
A
,
Buffet
M
,
Veyradier
A
, et al;
Experience of the French Thrombotic Microangiopathies Reference Center
.
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange
.
Crit Care Med.
2012
;
40
(
1
):
104
-
111
.
20.
Page
EE
,
Kremer Hovinga
JA
,
Terrell
DR
,
Vesely
SK
,
George
JN
.
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura
.
Blood.
2016
;
127
(
24
):
3092
-
3094
.
21.
Shortt
J
,
Oh
DH
,
Opat
SS
.
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura
.
N Engl J Med.
2013
;
368
(
1
):
90
-
92
.
22.
Mazepa
MA
,
Raval
JS
,
Moll
S
,
Ma
A
,
Park
YA
.
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura
.
Br J Haematol.
2014
;
164
(
6
):
900
-
902
.
23.
Patriquin
CJ
,
Thomas
MR
,
Dutt
T
, et al
.
Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura
.
Br J Haematol.
2016
;
173
(
5
):
779
-
785
.
24.
van den Berg
J
,
Kremer Hovinga
JA
,
Pfleger
C
, et al
.
Daratumumab for immune thrombotic thrombocytopenic purpura
.
Blood Adv.
2022
;
6
(
3
):
993
-
997
.
25.
Saidenberg
L
,
Arbini
AA
,
Silverman
GJ
,
Lotan
I
,
Cutter
G
,
Kister
I
.
Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases
.
Mult Scler Relat Disord.
2022
;
63
:
103830
.
26.
Menard
LC
,
Habte
S
,
Gonsiorek
W
, et al
.
B cells from African American lupus patients exhibit an activated phenotype
.
JCI Insight.
2016
;
1
(
9
):
e87310
.
27.
Ritterhouse
LL
,
Crowe
SR
,
Niewold
TB
, et al
.
B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels
.
Arthritis Rheum.
2011
;
63
(
12
):
3931
-
3941
.
28.
Díaz-Lagares
C
,
Croca
S
,
Sangle
S
, et al;
UK-BIOGEAS Registry
.
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts
.
Autoimmun Rev.
2012
;
11
(
5
):
357
-
364
.
29.
Rovin
BH
,
Furie
R
,
Latinis
K
, et al;
LUNAR Investigator Group
.
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study
.
Arthritis Rheum.
2012
;
64
(
4
):
1215
-
1226
.
30.
Martino
S
,
Jamme
M
,
Deligny
C
, et al;
French Reference Center for Thrombotic Microangiopathies
.
Thrombotic thrombocytopenic purpura in Black people: impact of ethnicity on survival and genetic risk factors
.
PLoS One.
2016
;
11
(
7
):
e0156679
.
31.
Thomas
MR
,
de Groot
R
,
Scully
MA
,
Crawley
JTB
.
Pathogenicity of Anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura
.
EBioMedicine.
2015
;
2
(
8
):
942
-
952
.
32.
Vichinsky
EP
,
Earles
A
,
Johnson
RA
,
Hoag
MS
,
Williams
A
,
Lubin
B
.
Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood
.
N Engl J Med.
1990
;
322
(
23
):
1617
-
1621
.
33.
Page
EE
,
Kremer Hovinga
JA
,
Terrell
DR
,
Vesely
SK
,
George
JN
.
Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura
.
Blood
.
2016
;
128
(
17
):
2175
-
2178
.
34.
Jin
M
,
Casper
TC
,
Cataland
SR
, et al
.
Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
.
Br J Haematol.
2008
;
141
(
5
):
651
-
658
.
35.
Peyvandi
F
,
Lavoretano
S
,
Palla
R
, et al
.
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission
.
Haematologica.
2008
;
93
(
2
):
232
-
239
.
36.
Turner
NA
,
Moake
J
.
Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis
.
PLoS One.
2013
;
8
(
3
):
e59372
.
You do not currently have access to this content.

Sign in via your Institution